Castle Biosciences, Inc. (NASDAQ:CSTL) Stock Has Consensus Price Target of $44.25 According to Brokerages

Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) have been given a consensus rating of “Moderate Buy” by the eleven analysts that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, eight have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $44.88.

CSTL has been the topic of a number of research reports. Wall Street Zen upgraded Castle Biosciences from a “hold” rating to a “buy” rating in a report on Sunday, November 1st. Robert W. Baird set a $36.00 price objective on shares of Castle Biosciences in a research report on Friday, July 31st. BTIG Research lifted their target price on shares of Castle Biosciences from $40.00 to $44.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. KeyCorp boosted their target price on shares of Castle Biosciences from $35.00 to $40.00 and gave the stock an “overweight” rating in a research report on Friday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Castle Biosciences in a research report on Thursday, October 29th.

Castle Biosciences Trading Down 4.9%

Castle Biosciences stock opened at $32.52 on Tuesday. Castle Biosciences has a 12 month low of $17.72 and a 12 month high of $44.28. The company has a quick ratio of 5.85, a current ratio of 6.04 and a debt-to-equity ratio of 0.02. The stock has a market cap of $993.49 million, a P/E ratio of -42.23 and a beta of 1.00. The company’s fifty day simple moving average is $34.25 and its 200-day simple moving average is $28.53.

Castle Biosciences (NASDAQ:CSTL) last announced its quarterly earnings data on Thursday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.22. The business had revenue of $101.95 million during the quarter, compared to analyst estimates of $92.77 million. Castle Biosciences had a negative return on equity of 4.92% and a negative net margin of 6.10%. As a group, sell-side analysts forecast that Castle Biosciences will post -1.29 EPS for the current fiscal year.

Key Stories Impacting Castle Biosciences

Here are the key news stories impacting Castle Biosciences this week:

• Positive Sentiment: Q3 revenue rose 24% year over year to $102.9 million, beating analyst expectations, and the per-share loss of $0.13 was narrower than forecasts. Castle Biosciences Reports Third Quarter 2026 Results
• Positive Sentiment: Management raised 2026 revenue guidance to $385–$395 million from $365–$375 million. TissueCypher test report volume increased 47% year over year, with the company signaling 50%–52% volume growth for the full year. Revenue outlook and TissueCypher growth
• Positive Sentiment: KeyCorp raised its price target to $40 from $35 and maintained an Overweight rating, signaling potential upside in the firm’s view. KeyCorp recommendations
• Negative Sentiment: The company remains unprofitable: its quarterly loss widened from $0.02 per share a year earlier to $0.13, despite beating analyst estimates. Ongoing losses could weigh on sentiment alongside the otherwise strong growth and guidance update. Q3 loss and revenue results

Insider Activity at Castle Biosciences

In other Castle Biosciences news, insider Tobin W. Juvenal sold 6,578 shares of the firm’s stock in a transaction dated Wednesday, October 28th. The stock was sold at an average price of $36.42, for a total transaction of $239,570.76. Following the transaction, the insider directly owned 38,853 shares in the company, valued at $1,415,026.26. This trade represents a 14.48% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Derek Maetzold sold 8,580 shares of the firm’s stock in a transaction dated Monday, October 19th. The shares were sold at an average price of $31.91, for a total value of $273,787.80. Following the transaction, the insider owned 12,484 shares in the company, valued at approximately $398,364.44. This trade represents a 40.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 126,184 shares of company stock valued at $4,324,506. Insiders own 6.10% of the company’s stock.

Institutional Trading of Castle Biosciences

Large investors have recently made changes to their positions in the stock. Advisors Capital Management LLC bought a new stake in shares of Castle Biosciences during the 2nd quarter worth $5,681,000. BlackRock Inc. acquired a new position in Castle Biosciences in the 2nd quarter valued at $78,513,000. Bank of New York Mellon Corp acquired a new position in Castle Biosciences in the 2nd quarter valued at $2,338,000. Empowered Funds LLC bought a new position in Castle Biosciences in the 2nd quarter worth $3,395,000. Finally, Quantinno Capital Management LP raised its holdings in Castle Biosciences by 387.3% in the 1st quarter. Quantinno Capital Management LP now owns 45,476 shares of the company’s stock worth $1,116,000 after acquiring an additional 36,144 shares during the period. Institutional investors own 92.60% of the company’s stock.

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company that develops and commercializes tests designed to help physicians diagnose cancer, assess disease risk and guide treatment decisions. The company focuses on conditions in which additional biological information can complement traditional pathology and clinical assessment.

Its portfolio includes DecisionDx-Melanoma, which helps evaluate the risk of metastatic recurrence in patients with cutaneous melanoma; DecisionDx-SCC, which assesses metastatic risk in cutaneous squamous cell carcinoma; and DecisionDx-UM, a test for determining metastatic risk in uveal melanoma.